Abstracts tagged "Human leukocyte antigens (HLA) and systemic lupus erythematosus (SLE)"

Abstract Number: 90 • 2015 ACR/ARHP Annual Meeting
Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans
So-Young Bang¹, Ji-Young Choi¹, Songree Park¹, Seung Lee², Jeongim Choi¹, Seung-Jae Hong³, Hye-Soon Lee¹, Chan-Bum Choi¹ and Sang-Cheol Bae¹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Kyung Hee University Hospital, seoul, South Korea
Background/Purpose: We investigated the association between human leukocyte antigen (HLA)-DRB1 alleles and systemic lupus erythematosus (SLE) susceptibility and whether each allele has a significant effect…
Abstract Number: 2954 • 2014 ACR/ARHP Annual Meeting
The Amino Acid Positions 11, 13 and 26 of HLA-DR Beta Chain 1 Explain the Majority of the Association Between Systemic Lupus Erythematosus and the Major Histocompatibility Complex Locus
Kwangwoo Kim^1,2,3, So-Young Bang⁴, Hye-Soon Lee⁴, Yukinori Okada^2,3,5, Woei-Yuh Saw⁶, Paul IW. de Bakker^2,3,7, Yik-Ying Teo^6,8, Soumya Raychaudhuri^2,9,10 and Sang-Cheol Bae¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Broad Institute, Cambridge, MA, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶National University of Singapore, Singapore, Singapore, ⁷Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, ⁹Broad Institute of MIT and Harvard, Cambridge, MA, ¹⁰Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Genetic association of the major histocompatibility complex (MHC) locus is well-established in systemic lupus erythematosus (SLE), but the causal functional variants in this region…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].